Get the Stockscreener App
0.81
9.27%
-0.0828
Esperion Therapeutics Inc stock is traded at $0.81, with a volume of 3.62M.
It is down -9.27% in the last 24 hours and down -22.86% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$0.8928
Open:
$0.9051
24h Volume:
3.62M
Relative Volume:
0.82
Market Cap:
$169.15M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-0.3821
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
-25.69%
1M Performance:
-22.86%
6M Performance:
-64.47%
1Y Performance:
-61.24%
1-Day Range:
$0.7995
$0.931
1-Week Range:
$0.7995
$1.10
52-Week Range:
$0.7995
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
0.8101 | 169.15M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
159.88 | 69.43B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 47.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.79 | 46.56B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.30 | 20.71B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
304.77 | 13.25B | 2.76B | 1.11B | 898.10M | 22.77 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines - Yahoo
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference - GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Stock Titan
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - MSN
Esperion at The Citizens JMP Life Sciences Conference: Strategic Growth Insights - Investing.com
Esperion, HLS partner for heart disease treatments in Canada - Seeking Alpha
HLS Therapeutics Partners with Esperion to Bring Cardiovascular Treatments to Canada - TipRanks
Esperion secures Canadian rights deal for heart drugs - Investing.com
Esperion Enters License Agreement with HLS Therapeutics to Expand Access to Bempedoic Acid Products in Canada - Nasdaq
Esperion secures Canadian rights deal for heart drugs By Investing.com - Investing.com Canada
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and ... - Bluefield Daily Telegraph
Esperion Therapeutics (ESPR) Partners with HLS Therapeutics to Commercialize NEXLETOL and NEXLIZET in Canada - StreetInsider
HLS Therapeutics Announces Q1 2025 Financial Results - Yahoo Finance
Esperion Partners with HLS Therapeutics to Commercialize - GlobeNewswire
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada - Stock Titan
Esperion outlines Q2 prescription growth, targets triple combo launch by 2027 - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2025 Earnings Call Transcript - Insider Monkey
Esperion Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Esperion Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Earnings call transcript: Esperion Q1 2025 misses EPS forecast, revenue grows - Investing.com Nigeria
Esperion Therapeutics (ESPR) Reports Strong Q1 2025 Revenue Grow - GuruFocus
Esperion Therapeutics (ESPR) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Esperion Q1 2025 slides: U.S. product sales surge 41% amid strategic expansion - Investing.com
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Esperion Reports First Quarter 2025 Financial Results - GlobeNewswire
BRIEF-Esperion Therapeutics Q1 Basic EPS USD -0.21 - TradingView
Esperion Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Esperion Reveals Next-Gen Cholesterol Treatment Strategy: FDA-Approved Non-Statin Leader Updates Growth Plans - Stock Titan
Esperion to Participate in The Citizens Life Sciences Conference - The Manila Times
Esperion unveils novel PSC treatment candidates By Investing.com - Investing.com Canada
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Esperion (ESPR) Advances ACLY Inhibitors for Rare Liver Disease Treatment | ESPR Stock News - GuruFocus
Esperion unveils novel PSC treatment candidates - Investing.com
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 - The Manila Times
New PSC Liver Disease Treatment Breakthrough: Promising Data Reveals Path to $1B Market Opportunity - Stock Titan
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Esperion to Report First Quarter 2025 Financial Results on May 6 - The Manila Times
Esperion Q1 2025 Earnings Preview: What's Next for this FDA-Approved Cardiovascular Drug Maker? - Stock Titan
Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Esperion stock hits 52-week low at $0.91 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $0.91 amid challenges - Investing.com
Esperion Therapeutics (ESPR) Faces Downward Earnings Estimate Re - GuruFocus
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 - The Manila Times
Esperion to Host R&D Day to Highlight Cardiometabolic - GlobeNewswire
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):